Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study)
I Gentile, View ORCID ProfileA Giaccone, MM Scirocco, F Di Brizzi, F Cuccurullo, M Silvitelli, L Ametrano, FA Alfè, D Pietroluongo, I Irace, MR Chiariello, N De Felice, S Severino, View ORCID ProfileG Viceconte, View ORCID ProfileN Schiano Moriello, AE Maraolo, AR Buonomo, R Scotto, Federico II COVID team
doi: https://doi.org/10.1101/2024.06.07.24307681
I Gentile
1Department of Clinical Medicine and Surgery – Section of Infectious Diseases, University of Naples Federico II, Italy
A Giaccone
2AORN Ospedali dei Colli, Cotugno Hospital, Department of Infectious Diseases, Unit of Geriatric Infectious Diseases, Naples, Italy
MM Scirocco
1Department of Clinical Medicine and Surgery – Section of Infectious Diseases, University of Naples Federico II, Italy
F Di Brizzi
1Department of Clinical Medicine and Surgery – Section of Infectious Diseases, University of Naples Federico II, Italy
F Cuccurullo
1Department of Clinical Medicine and Surgery – Section of Infectious Diseases, University of Naples Federico II, Italy
M Silvitelli
1Department of Clinical Medicine and Surgery – Section of Infectious Diseases, University of Naples Federico II, Italy
L Ametrano
1Department of Clinical Medicine and Surgery – Section of Infectious Diseases, University of Naples Federico II, Italy
FA Alfè
1Department of Clinical Medicine and Surgery – Section of Infectious Diseases, University of Naples Federico II, Italy
D Pietroluongo
1Department of Clinical Medicine and Surgery – Section of Infectious Diseases, University of Naples Federico II, Italy
I Irace
1Department of Clinical Medicine and Surgery – Section of Infectious Diseases, University of Naples Federico II, Italy
MR Chiariello
1Department of Clinical Medicine and Surgery – Section of Infectious Diseases, University of Naples Federico II, Italy
N De Felice
1Department of Clinical Medicine and Surgery – Section of Infectious Diseases, University of Naples Federico II, Italy
S Severino
1Department of Clinical Medicine and Surgery – Section of Infectious Diseases, University of Naples Federico II, Italy
G Viceconte
1Department of Clinical Medicine and Surgery – Section of Infectious Diseases, University of Naples Federico II, Italy
N Schiano Moriello
1Department of Clinical Medicine and Surgery – Section of Infectious Diseases, University of Naples Federico II, Italy
AE Maraolo
1Department of Clinical Medicine and Surgery – Section of Infectious Diseases, University of Naples Federico II, Italy
AR Buonomo
1Department of Clinical Medicine and Surgery – Section of Infectious Diseases, University of Naples Federico II, Italy
R Scotto
1Department of Clinical Medicine and Surgery – Section of Infectious Diseases, University of Naples Federico II, Italy
Data Availability
The datasets generated and/or analysed during the current study, along with the Case Report Forms (CRFs), the written informed consent from case participants, and the records of the telephonic interviews conducted with control participants, including their verbal informed consent, are stored by the data manager at the Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini 5, 80131, Naples, Italy. These can be retrieved and reviewed upon request by any relevant authority.
Posted June 07, 2024.
Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study)
I Gentile, A Giaccone, MM Scirocco, F Di Brizzi, F Cuccurullo, M Silvitelli, L Ametrano, FA Alfè, D Pietroluongo, I Irace, MR Chiariello, N De Felice, S Severino, G Viceconte, N Schiano Moriello, AE Maraolo, AR Buonomo, R Scotto, Federico II COVID team
medRxiv 2024.06.07.24307681; doi: https://doi.org/10.1101/2024.06.07.24307681
Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study)
I Gentile, A Giaccone, MM Scirocco, F Di Brizzi, F Cuccurullo, M Silvitelli, L Ametrano, FA Alfè, D Pietroluongo, I Irace, MR Chiariello, N De Felice, S Severino, G Viceconte, N Schiano Moriello, AE Maraolo, AR Buonomo, R Scotto, Federico II COVID team
medRxiv 2024.06.07.24307681; doi: https://doi.org/10.1101/2024.06.07.24307681
Subject Area
Subject Areas
- Addiction Medicine (362)
- Allergy and Immunology (682)
- Anesthesia (182)
- Cardiovascular Medicine (2719)
- Dermatology (233)
- Emergency Medicine (410)
- Epidemiology (12362)
- Forensic Medicine (10)
- Gastroenterology (781)
- Genetic and Genomic Medicine (4214)
- Geriatric Medicine (394)
- Health Economics (696)
- Health Informatics (2722)
- Health Policy (1012)
- Hematology (369)
- HIV/AIDS (872)
- Medical Education (403)
- Medical Ethics (111)
- Nephrology (449)
- Neurology (3997)
- Nursing (216)
- Nutrition (592)
- Oncology (2104)
- Ophthalmology (600)
- Orthopedics (250)
- Otolaryngology (309)
- Pain Medicine (256)
- Palliative Medicine (77)
- Pathology (475)
- Pediatrics (1141)
- Primary Care Research (464)
- Public and Global Health (6620)
- Radiology and Imaging (1435)
- Respiratory Medicine (881)
- Rheumatology (417)
- Sports Medicine (350)
- Surgery (458)
- Toxicology (57)
- Transplantation (192)
- Urology (171)